Dibutyltin oxide → HCID 178488420, 화합물

반응식

[CH3:1][O:2][C:3]1[CH:8]=[CH:7][C:6]([C:9]2[C:17]3[C:16]([NH:18][CH2:19][CH2:20][CH2:21][O:22][CH2:23][CH2:24][C:25]#[N:26])=[N:15][CH:14]=[N:13][C:12]=3[O:11][C:10]=2[C:27]2[CH:32]=[CH:31][CH:30]=[CH:29][CH:28]=2)=[CH:5][CH:4]=1.C[Si]([N:37]=[N+:38]=[N-:39])(C)C.C([Sn](=O)CCCC)CCC>C1(C)C=CC=CC=1>[CH3:1][O:2][C:3]1[CH:4]=[CH:5][C:6]([C:9]2[C:17]3[C:16]([NH:18][CH2:19][CH2:20][CH2:21][O:22][CH2:23][CH2:24][C:25]4[NH:39][N:38]=[N:37][N:26]=4)=[N:15][CH:14]=[N:13][C:12]=3[O:11][C:10]=2[C:27]2[CH:28]=[CH:29][CH:30]=[CH:31][CH:32]=2)=[CH:7][CH:8]=1

참가 물질

실험 절차

Stir 137 mg (0.32 mmol) 5-(4-methoxyphenyl)-6-phenyl-N-{3-[2-cyanoethoxy]propyl}furo[2,3-d]-pyrimidine-4-amine, 552 mg (4.8 mmol) trimethylsilylazide and 119 mg (0.48 mmol) di-n-butyltin oxide in 10 ml toluene overnight at 80° C. Then cool the mixture and concentrate by evaporation. Dissolve the residue that remains in methylene chloride and wash with water and sodium chloride solution. Dry the organic phase over magnesium sulphate and concentrate in the rotary evaporator at reduced pressure. Purify the residue by RP-HPLC (column: Gromsil 250 mm×30 mm, 10 μm; acetonitrile/water gradient: 0-3 min 5% acetonitrile, 3-34 min 5%→98% acetonitrile, 34-38 min 98% acetonitrile). 48.6 mg (32% of theor.) of the title compound is obtained as a colourless solid.